BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9875675)

  • 1. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12.
    Zoll B; Lefterova P; Csipai M; Finke S; Trojaneck B; Ebert O; Micka B; Roigk K; Fehlinger M; Schmidt-Wolf GD; Huhn D; Schmidt-Wolf IG
    Cancer Immunol Immunother; 1998 Dec; 47(4):221-6. PubMed ID: 9875675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation.
    Zoll B; Lefterova P; Ebert O; Huhn D; Von Ruecker A; Schmidt-Wolf IG
    Cytokine; 2000 Sep; 12(9):1385-90. PubMed ID: 10975999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
    Naume B; Gately M; Espevik T
    J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
    Alderson MR; Sassenfeld HM; Widmer MB
    J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of interleukin 10 on interleukin 12- and interleukin 2-mediated killer induction from blood mononuclear cells.
    Pai K; Yanagawa H; Takauchi E; Suzuki Y; Hanibuchi M; Parajuli P; Sone S
    Oncol Res; 1998; 10(6):295-300. PubMed ID: 9848100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
    Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
    Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
    Ozdemir O; Ravindranath Y; Savaşan S
    J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon gamma production in interleukin-2-activated T cells.
    Chong AS; Jiang XL; Scuderi P; Lamas M; Graf LH
    Cancer Immunol Immunother; 1994 Aug; 39(2):127-34. PubMed ID: 7519126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12.
    Naume B; Johnsen AC; Espevik T; Sundan A
    Eur J Immunol; 1993 Aug; 23(8):1831-8. PubMed ID: 7688307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15.
    Seder RA; Grabstein KH; Berzofsky JA; McDyer JF
    J Exp Med; 1995 Oct; 182(4):1067-77. PubMed ID: 7561680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
    Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
    Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma.
    Kondo M; Nonomura N; Miki T; Kojima Y; Yokoyama M; Nakano E; Okuyama A
    Oncology; 1998; 55(6):588-93. PubMed ID: 9778628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects and mechanism on anti-leukemic activity of cytokine-induced killer cells with an endogenous expression of interleukin-21].
    Zhao N; Zhao MF; Rajbhandary S; Lu WY; Zhu HB; Ma L; You Q; Xiao X; Deng Q; Li YM
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(4):293-9. PubMed ID: 23578511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.